IBOV 169,672.46 ▼ 0.08% IPC MEX 70,388.96 ▼ 1.15% MERVAL 2,848,945 — — USD/BRL5.79▲ 0.17% USD/MXN18.56▲ 0.74% USD/CLP999.88▲ 0.71% USD/COP3,317▼ 0.01% USD/PEN3.41▲ 0.05% USD/ARS1,557▲ 0.31% USD/UYU40.61▲ 3.30% USD/PYG6,212▲ 3.32% USD/BOB11.64▲ 3.07% USD/DOP60.01▼ 0.48% USD/CRC441.73▲ 2.50% USD/GTQ7.64▲ 3.28% USD/HNL26.89▼ 0.10% USD/NIO36.62▲ 0.34% USD/VES913.46▼ 0.22% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.39▲ 2.57% USD/TTD6.70▲ 1.98% EUR/BRL6.35▼ 0.05% BRENT 89.86 ▼ 3.52% WTI 83.80 ▼ 2.57% IRON ORE 161.91 — — COPPER 5.73 ▼ 4.08% GOLD 3,789 ▼ 1.95% SILVER 45.87 ▼ 3.00% SOY 1,222 ▼ 0.29% CORN 444.25 ▼ 0.56% WHEAT 603.25 ▲ 1.34% COFFEE 275.80 ▼ 3.77% SUGAR 18.06 ▼ 0.61% ORANGE JUICE 133.30 ▼ 1.26% COTTON 80.95 ▲ 4.69% COCOA 5,028 ▼ 0.04% BEEF 218.70 ▼ 0.74% CATTLE 335.50 ▼ 0.56% LITHIUM 56.42 ▼ 0.74% PETR4 43.90 ▼ 0.18% VALE3 59.88 ▼ 0.76% ITUB4 40.92 ▲ 0.07% BBDC4 14.46 ▲ 0.35% ABEV3 15.96 ▲ 0.19% BBAS3 14.69 ▲ 0.48% B3SA3 14.53 ▼ 0.82% WEGE3 51.72 ▲ 1.11% PRIO3 63.56 ▼ 0.63% SUZB3 56.36 ▲ 1.75% RENT3 29.74 ▲ 0.27% AZZA3 15.88 ▲ 1.53% CSAN3 3.21 ▼ 1.23% RAIZ4 18.49 ▼ 3.24% PCAR3 3.01 ▲ 4.15% GMAT3 4.16 ▼ 0.48% PSSA3 45.48 ▼ 0.96% CVCB3 0.77 ▼ 1.28% POSI3 3.15 ▲ 0.64% SLCE3 18.03 ▼ 0.17% NATU3 4.69 ▼ 1.26% BRKM5 2.79 ▲ 1.45% RANI3 8.11 ▼ 1.34% CSNA3 3.78 ▲ 0.27% IBOV 169,672.46 ▼ 0.08% IPC MEX 70,388.96 ▼ 1.15% MERVAL 2,848,945 — — USD/BRL 5.80 ▲ 0.31% USD/MXN 18.56 ▲ 0.77% USD/CLP 999.31 ▲ 0.65% USD/COP 3,311 ▼ 0.18% USD/PEN 3.41 ▲ 0.05% USD/ARS 1,556 ▲ 0.21% USD/UYU 40.61 ▲ 3.30% USD/PYG 6,212 ▲ 3.32% USD/BOB 11.64 ▲ 3.07% USD/DOP 60.01 ▼ 0.48% USD/CRC 441.73 ▲ 2.50% USD/GTQ 7.64 ▲ 3.28% USD/HNL 26.89 ▼ 0.10% USD/NIO 36.62 ▲ 0.34% USD/VES 913.46 ▼ 0.22% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.39 ▲ 2.57% USD/TTD 6.70 ▲ 1.98% EUR/BRL 6.36 ▲ 0.09% BRENT 89.86 ▼ 3.52% WTI 83.80 ▼ 2.57% IRON ORE 161.91 — — COPPER 5.73 ▼ 4.08% GOLD 3,789 ▼ 1.95% SILVER 45.87 ▼ 3.00% SOY 1,222 ▼ 0.29% CORN 444.25 ▼ 0.56% WHEAT 603.25 ▲ 1.34% COFFEE 275.80 ▼ 3.77% SUGAR 18.06 ▼ 0.61% ORANGE JUICE 133.30 ▼ 1.26% COTTON 80.95 ▲ 4.69% COCOA 5,028 ▼ 0.04% BEEF 218.70 ▼ 0.74% CATTLE 335.50 ▼ 0.56% LITHIUM 56.42 ▼ 0.74% PETR4 43.90 ▼ 0.18% VALE3 59.88 ▼ 0.76% ITUB4 40.92 ▲ 0.07% BBDC4 14.46 ▲ 0.35% ABEV3 15.96 ▲ 0.19% BBAS3 14.69 ▲ 0.48% B3SA3 14.53 ▼ 0.82% WEGE3 51.72 ▲ 1.11% PRIO3 63.56 ▼ 0.63% SUZB3 56.36 ▲ 1.75% RENT3 29.74 ▲ 0.27% AZZA3 15.88 ▲ 1.53% CSAN3 3.21 ▼ 1.23% RAIZ4 18.49 ▼ 3.24% PCAR3 3.01 ▲ 4.15% GMAT3 4.16 ▼ 0.48% PSSA3 45.48 ▼ 0.96% CVCB3 0.77 ▼ 1.28% POSI3 3.15 ▲ 0.64% SLCE3 18.03 ▼ 0.17% NATU3 4.69 ▼ 1.26% BRKM5 2.79 ▲ 1.45% RANI3 8.11 ▼ 1.34% CSNA3 3.78 ▲ 0.27%
since 2009
Wednesday, November 18, 2026

Covid-19 Brazil

Covid -19: Moderna vaccine guarantees protection longer than Pfizer/BioNTech – CDC study

By · · 2 min read

RIO DE JANEIRO, BRAZIL – A new study published Friday, 17, by the U.S. Centers for Disease Control and Prevention (CDC) is the latest to suggest that Moderna’s Covid-19 vaccine confers greater long-term protection against hospitalization than Pfizer’s.

Over the entire period, between March 11 and August 15, 2021 – the period leading up to and including the peak of the delta variant – Moderna’s vaccine was 93% effective against hospitalization, Pfizer’s was 88%, and J&J’s was 68%.

CDC researchers analyzed nearly 3,689 adults who were hospitalized with severe covid-19 between March 11 and August 15, 2021.

Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.
Covid -19: Moderna vaccine guarantees protection longer than Pfizer/BioNTech – CDC study
Moderna’s vaccine produced higher levels of antibodies compared to Pfizer’s and J&J’s for an essential part of the coronavirus “spike” protein, which is used to invade cells
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Overall, 12.9% of them were fully vaccinated with Moderna’s doses, 20.0% with Pfizer/BioNTech, and 3.1% with Johnson & Johnson.

The loss of effectiveness against hospitalization for Pfizer was especially pronounced: it dropped from 91% between 14 and 120 days after vaccination to 77% more than 120 days after vaccination. On the other hand, Moderna dropped from 93% to 92% when comparing the same two periods.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “US Embassy warns Americans of Colombia strike Thursday”

The study also included a separate analysis of the vaccines’ levels of different types of antibodies collected from 100 volunteers.

Moderna’s vaccine produced higher antibodies levels than Pfizer’s and J&J’s for an essential part of the coronavirus “spike” protein, which is used to invade cells.

Research suggesting the superiority of Moderna’s vaccine over Pfizer’s is growing, including an earlier CDC study published last week. The reasons are not entirely determined but may be related to the higher dose levels: 100 micrograms versus 30. They may also be related to the interval between doses, as Pfizer’s injections are given three weeks apart in the United States, while Moderna’s are four weeks apart.

The Food and Drug Administration (FDA) is holding a meeting of leading independent experts on Friday to discuss a possible third dose of Pfizer for the general population and not just for immunosuppressed people.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.